Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Neurocrine Biosciences has reported Finished Goods for 9 years, with the latest figure at $13.6 million in Q1 2025.

• For the quarter ending Q1 2025, Finished Goods rose 81.33% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2025 stood at $13.6 million (up 81.33% YoY), and the FY2024 full-year result was $12.8 million, up 4.07% from the prior year.
• Finished Goods for Q1 2025 stood at $13.6 million, up from $12.8 million in the prior quarter.
• The five-year high for Finished Goods was $17.5 million in Q4 2022, with the low at $7.5 million in Q1 2024.
• Historically, Finished Goods has averaged $12.7 million across 5 years, with a median of $12.5 million in 2023.
• Annual changes were most pronounced in 2023 — Finished Goods slipped 29.71% — and 2025, when it soared 81.33%.
• Neurocrine Biosciences' Finished Goods stood at $15.7 million in 2021, then increased by 11.46% to $17.5 million in 2022, then fell by 29.71% to $12.3 million in 2023, then climbed by 4.07% to $12.8 million in 2024, then advanced by 6.25% to $13.6 million in 2025.
• The last three Finished Goods figures came in at $13.6 million (Q1 2025), $12.8 million (Q4 2024), and $11.5 million (Q3 2024), per Business Quant data.